drugset / Trial / NCT02527421

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

NCT02527421

Phase 3 Terminated 3 enrolled Primus Pharmaceuticals Prosoft Clinical · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Timeline

Start
2015-08-19
Primary completion
2019-03-30
Completion
2019-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject betamethasone dipropionate Small molecule 0.05 % Topical

Indications